Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can we increase adolescent growth?

Jean Claude Carel1

  • 1Department of Pediatric Endocrinology and INSERM U561, Groupe Hospitalier Cochin-Saint Vincent de Paul and Faculte Cochin-Universite Paris V, Paris, France. carel@paris5.inserm.fr

European Journal of Endocrinology
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitchell-Riley Syndrome: Improving Clinical Outcomes and Searching for Functional Impact of RFX-6 Mutations.

Frontiers in endocrinology·2022
Same author

Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome).

Annales d'endocrinologie·2021
Same author

Hyponatremia in children under 100 days old: incidence and etiologies.

European journal of pediatrics·2019
Same author

High prevalence of syndromic disorders in patients with non-isolated central precocious puberty.

European journal of endocrinology·2018
Same author

Diagnosis and management of hyperthyroidism from prenatal life to adolescence.

Best practice & research. Clinical endocrinology & metabolism·2018
Same author

Association of maternal nutrition with transient neonatal hyperinsulinism.

PloS one·2018
Same journal

Psychosocial retrospective follow-up of young adults with congenital adrenal hyperplasia.

European journal of endocrinology·2026
Same journal

Correction to: Steroidogenic factor-1 regulates a core set of target genes to promote malignancy in adrenocortical carcinoma.

European journal of endocrinology·2026
Same journal

Improving post-thyroidectomy care using a PTH and calcium-based algorithm.

European journal of endocrinology·2026
Same journal

Sampling variability and concordance between sequential and simultaneous adrenal venous sampling in primary aldosteronism subtype diagnosis.

European journal of endocrinology·2026
Same journal

Independent Clonal Evolution in Primary Pigmented Nodular Adrenocortical Disease: A Single-Patient Multi-Omics Study.

European journal of endocrinology·2026
Same journal

Twenty years of neurosurgical experience with Cushing's disease: surgical-strategies, endocrine outcomes and remission predictors in 346 patients.

European journal of endocrinology·2026
See all related articles

Treatments for short adolescents offer modest height gains, with growth hormone and GnRH agonists showing limited efficacy and potential risks. Further research is needed to determine clinical significance and cost-benefit balance.

Area of Science:

  • Pediatric Endocrinology
  • Adolescent Medicine
  • Growth Disorders

Background:

  • Adolescent growth spurt accounts for 15-20% of adult height.
  • Early puberty is a critical period for height assessment and intervention.
  • Current interventions aim to enhance the pubertal growth spurt in short children.

Purpose of the Study:

  • To review current treatment approaches for increasing pubertal growth in short children.
  • To evaluate the results and risks associated with these interventions.
  • To assess the clinical significance and cost-benefit balance of growth-enhancing therapies.

Main Methods:

  • Review of current literature on interventions for adolescent growth.
  • Analysis of data on growth hormone (GH) therapy.

Related Experiment Videos

  • Analysis of data on Gonadotropin-releasing hormone (GnRH) agonist therapy.
  • Evaluation of combined GH and GnRH agonist therapy.

    • Main Results:

    • GnRH agonists used for over 3 years yield a modest height gain (approx. 4 cm) with potential effects on bone mass, body composition, and psychosocial parameters.
    • Growth hormone (GH) therapy has shown to increase adult height in short adolescents with idiopathic short stature or born small for gestational age, though effects are modest.
    • Combined GH and GnRH agonist therapy is popular but lacks definitive efficacy data.

    Conclusions:

    • Current treatments provide insight into median effects but initial overoptimism has been tempered.
    • The clinical significance and cost-benefit balance of these interventions require further evaluation.
    • Understanding individual response variability to these treatments remains a significant challenge.